Journal of Public Health Policy

, Volume 31, Issue 4, pp 422–432 | Cite as

Prescription drug laws, drug overdoses, and drug sales in New York and Pennsylvania

  • Leonard J Paulozzi
  • Daniel D Stier
Original Article


Drug overdose mortality nearly doubled in the United States from 1999 to 2004, with most of the increase due to prescription drug overdoses. Studying mortality rates in states that did not experience such increases may identify successful prescription overdose prevention strategies. We compared New York, a state that did not experience an overdose increase, with its neighbor, Pennsylvania. New York and Pennsylvania had prescription drug monitoring programs (PDMPs), but New York's PDMP was better funded and made use of serialized, tamperproof prescription forms. Per capita usage of the major prescription opioids in New York was two-thirds that of Pennsylvania. The drug overdose death rate in Pennsylvania was 1.6 times that of New York in 2006. Differences between New York and Pennsylvania might be due to the regulatory environment in New York State.


opioid overdose regulation drug abuse poisoning mortality 



Special thanks to those who contributed information about their state laws and programs: Jennifer Treacy in New York and Lawrence Cherba in Pennsylvania; also to John Eadie for his helpful comments on an earlier version of this article.


  1. Centers for Disease Control and Prevention. WONDER [Online]. (2009) Centers for Disease Control and Prevention (producer),, accessed 21 August 2009.
  2. Fingerhut, L.A. and Anderson, R.N. (2008) The Three Leading Causes of Injury Mortality in the United States, 1999–2005. Hyattsville, MD: National Center for Health Statistics.Google Scholar
  3. Paulozzi, L.J. and Xi, Y. (2008) Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiology and Drug Safety 17 (10): 997–1005.CrossRefGoogle Scholar
  4. Paulozzi, L.J. and Annest, J.L. (2007) Unintentional poisoning deaths – United States, 1999–2004. Morbidity and Mortality Weekly Report 56: 93–96.Google Scholar
  5. Warner, M., Chen, L.J. and Makuc, D.M. (2009) Increase in Fatal Poisonings Involving Opioid Analgesics in the United States, 1999–2006. Hyattsville, MD: National Center for Health Statistics.CrossRefGoogle Scholar
  6. Hall, A.J., Logan, J.E., Toblin, R.L., Kaplan, J.A., Kraner, J.C. and Bixler, D. et al (2008) Patterns of abuse among unintentional pharmaceutical overdose fatalities. Journal of the American Medical Association 300 (22): 2613–2620.CrossRefGoogle Scholar
  7. Controlled Substances Act, 21 USC 801 et seq 2002. (GENERIC).Google Scholar
  8. Simeone, R. and Holland, L. (2006) An Evaluation of Prescription Drug Monitoring Programs. Washington DC: US Dept. of Justice, Office of Justice Programs.CrossRefGoogle Scholar
  9. US General Accounting Office. (2002) Prescription Drugs: State Monitoring Programs Provide Useful Tool to Reduce Diversion. Washington DC: US General Accounting Office, Report No. GAO-02-634.Google Scholar
  10. US Department of Justice Drug Enforcement Administration. (2008) Prescription drug monitoring programs,, accessed 15 October 2008.
  11. National Alliance for Model State Drug Laws. (2010) Prescription drug monitoring project,, accessed 10 May 2010.
  12. US Department of Commerce Census Bureau. (2006) 2000 Census, Summary File 3, Table P.5 urban and rural,, accessed 15 December 2006.
  13. US Department of Justice (USDOJ) Drug Enforcement Administration. (2009) ARCOS: Automation of reports and consolidated orders system,, accessed 27 March 2009.
  14. Curtis, L.H., Stoddard, J., Radeva, J.I., Hutchison, S., Dans, P.E. and Wright, A. et al (2006) Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Services Research 41 (3): 837–855.CrossRefGoogle Scholar
  15. Brixner, D.I., Oderda, G.M., Roland, C.L. and Rublee, D.A. (2006) Opioid expenditures and utilization in the Medicaid system. Journal of Pain & Palliative Care Pharmacotherapy 20 (1): 5–13.CrossRefGoogle Scholar
  16. Substance Abuse and Mental Health Services Administration. (2009) Drug Abuse Warning Network, 2007: Area Profiles of Drug-Related Mortality. Rockville, MD: SAMHSA.Google Scholar
  17. Piper, T.M., Rudenstine, S., Stancliff, S., Sherman, S., Nandi, V. and Clear, A. et al (2007) Overdose prevention for injection drug users: Lessons learned from naloxone training and distribution programs in New York City. Harm Reduction Journal 4: 1–8.CrossRefGoogle Scholar
  18. Office of the Inspector General. (1992) Multiple Copy Prescription Programs: State Experiences. Washington DC: Department of Health and Human Services, Report No. OEI-12-91-00490.Google Scholar
  19. Bishop, M.T. and Vlasty, R.J. (1993) The Illinois experience in achieving the medical/regulatory balance required to control prescription drug diversion. NIDA Research Monographs, 131, pp. 159–175.Google Scholar
  20. Ross-Degnan, D., Simoni-Wastila, L., Brown, J.F., Gao, X., Mah, C. and Cosler, L.E. et al (2004) A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. International Journal of Psychiatry in Medicine 34 (2): 103–123.CrossRefGoogle Scholar
  21. Wastila, L. and Bishop, C. (1996) The influence of multiple copy prescription programs on analgesic utilization. Journal of Pharmaceutical Care in Pain and Symptom Control 4 (3): 3–19.CrossRefGoogle Scholar
  22. Weintraub, M., Singh, S., Byrne, L., Maharaj, K. and Guttmacher, L. (1991) Consequences of the 1989 New York state triplicate benzodiazepine prescription regulations. Journal of the American Medical Association 266: 2392–2397.CrossRefGoogle Scholar
  23. Boudreau, D., Von, Korff M., Rutter, C.M., Saunders, K., Ray, G.T. and Sullivan, M.D. et al (2009) Trends in long-term opioid therapy for chronic non-cancer pain. Phamacoepidemiol Drug Safety 18 (12): 1166–1175.CrossRefGoogle Scholar
  24. Von Korff, M., Saunders, K., Ray, G., Boudreau, D., Campbell, C. and Merrill, J. et al (2008) De facto long-term opioid therapy for noncancer pain. The Clinical Journal of Pain 24 (6): 521–527.CrossRefGoogle Scholar
  25. New York State Department of Health. (2010) State prescription forms reducing fraud and abuse,, accessed 10 May 2010.
  26. Bolen, J. (2010) State opioid prescribing policy: New Jersey,, accessed 17 May 2010.
  27. Katz, N., Houle, B., Fernandez, K.C., Kreiner, P., Thomas, C.P. and Kim, M. et al (2008) Update on prescription monitoring in clinical practice: A survey study of prescription monitoring program administrators. Pain Medicine 9 (5): 587–594.CrossRefGoogle Scholar
  28. Lambert, D. (2010) Impact evaluation of Maine's prescription drug monitoring program,, accessed 10 May 2010.
  29. Forgione, D.A., Neuenschwander, P. and Vermeer, T.E. (2001) Diversion of prescription drugs to the black market: What the states are doing to curb the tide. Journal of Health Care Finance 27 (4): 65–78.Google Scholar
  30. Turk, D.C., Brody, M.C. and Okifuji, E.A. (1994) Physicians’ attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain 59 (2): 201–208.CrossRefGoogle Scholar
  31. Baehren, D.F., Marco, C.A., Droz, D.E., Sinha, S., Callan, E.M. and Akpunonu, P. (2009) A statewide prescription monitoring program affects emergency department prescribing behaviors. Annals of Emergency Medicine 56 (1): 19–23.CrossRefGoogle Scholar
  32. Tonry, M. (1996) Sentencing Matters. New York: Oxford University Press.Google Scholar

Copyright information

© Palgrave Macmillan, a division of Macmillan Publishers Ltd 2010

Authors and Affiliations

  • Leonard J Paulozzi
    • 1
  • Daniel D Stier
    • 2
  1. 1.Division of Unintentional Injury PreventionNational Center for Injury Prevention and Control, Centers for Disease Control and PreventionAtlantaUSA
  2. 2.Public Health Law Network, William Mitchell College of LawSt. PaulUSA

Personalised recommendations